Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

41
Caladrius Biosciences Strikes Gold With Acquisition Of Late-Stage Refractory Angina Therapy From Shire

2018-06-26 seekingalpha
Acquisition of CD34+ program to treat refractory angina from Shire with all regulatory filings gives Caladrius a mature product with good potential for approval.
CLBS BAX

176
Your Daily Pharma Scoop: Anika Fails Trial, Kala's Upcoming Catalyst, Sarepta Surges

2018-06-21 seekingalpha
Anika Therapeutics (ANIK) announced failure of its candidate CINGAL to achieve primary endpoint in a Phase 3 clinical trial in knee osteoarthritis (‘OA). CINGAL could not succeed in showing a statistically significant reduction in knee pain. CINGAL is a combination anti-inflammatory formula that combines hyaluronic acid (‘HA) with a steroid (triamcinolone hexacetonide). HA serves as a lubricant for arthritic joints.
NTLA CYAD AMGN ANIK PSTI CRSP SRPT MDWD CANF AMPH NVUS RSLS ALXN ALNA KALA CYAD CLBS PRTA PSTIW

8
CLBS / Caladrius Biosciences, Inc. S-8

2018-06-20 sec.gov
Document As filed with the Securities and Exchange Commission on June 20, 2018
CLBS

11
CLBS / Caladrius Biosciences, Inc. S-8

2018-06-20 sec.gov
Document As filed with the Securities and Exchange Commission on June 20, 2018
CLBS

8
CLBS / Caladrius Biosciences, Inc. 8-K (Current Report)

2018-06-20 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION
CLBS

4
Caladrius Biosciences' (CLBS) CEO David Mazzo on Q1 2018 Results - Earnings Call Transcript

2018-05-10 seekingalpha
Caladrius Biosciences, Inc. (NASDAQ:CLBS) Q1 2018 Results Earnings Conference Call May 10, 2018 4:30 PM ET
CLBS

7
CLBS / Caladrius Biosciences, Inc. 10-Q 2018 03 31 (Quarterly Report)

2018-05-10 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION
CLBS

21
CLBS / Caladrius Biosciences, Inc. DEFA14A -2018

2018-04-24 sec.gov
Document UNITED STATES
CLBS

11
CLBS / Caladrius Biosciences, Inc. DEF 14A

2018-04-24 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION
CLBS

303
Your Daily Pharma Scoop: vTv Therapeutics Plunges, Spectrum Provides Updated Data, Selecta Sees Pullback On Data

2018-04-11 seekingalpha
Today we will discuss vTv Therapeutics (NASDAQ:VTVT), which has seen three quarters of its market capitalization wiped off after the failure of a late-stage Alzheimer’s study. The failure once again highlights the fact that Alzheimer’s remains a difficult to treat area.
SPPI KPTI LOXO ZYNE KDMN ILMN VTVT SELB WVE BGNE CLBS SLB AXON

4
Caladrius Biosciences to Participate at Upcoming April Conferences

2018-04-09 globenewswire
BASKING RIDGE, N.J., April 09, 2018 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq:CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiovascular indications, announces today that Douglas Losordo, M.D., FACC, FAHA, Senior Vice President of Clinical Medical and Regulatory Affairs and Chief Medical Officer, will participate at the following conferences in April:
CLBS

4
Caladrius Biosciences to Present at The MicroCap Conference

2018-04-03 globenewswire
BASKING RIDGE, N.J., April 03, 2018 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq:CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiovascular indications, announces today that Joe Talamo, Senior Vice President and Chief Financial Officer, will present a corporate overview at The MicroCap Conference on Monday, April 9th at 1:30 p.
CLBS

5
CLBS / Caladrius Biosciences, Inc. 10-K/A (Annual Report)

2018-04-02 sec.gov
Document UNITED STATES SECURITI
CLBS

4
Caladrius Biosciences' (CLBS) CEO David Mazzo on Q4 2017 Results - Earnings Call Transcript

2018-03-22 seekingalpha
Caladrius Biosciences, Inc. (NASDAQ:CLBS) Q4 2017 Results Earnings Conference Call March 22, 2018 4:30 PM ET
CLBS

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

8h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

9h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 128058104